Related Topics News -

     
 Title only   |   Print 
     
勁方醫藥:Pan RAS抑制劑GFH276具獨立知識產權 不存在類似侵權或商業秘密爭議風險

2026-04-28T  
勁方醫藥KRAS G12D抑制劑納入突破性療法認定名單

2026-04-09T  
《大行》里昂升勁方醫藥目標價至61.9元 評級「跑贏大市」

2026-03-26T  
《業績》勁方醫藥去年虧損擴大至17.94億元人民幣

2026-03-25T  
勁方醫藥將於AACR年會展示三款產品臨床前研究數據

2026-03-22T  
勁方醫藥獲納入港股通證券名單

2026-03-09T  
勁方醫藥-B口服GFH375納入突破性療法認定名單

2026-03-02T  
《大行》交銀國際料醫藥板塊今年持續穩中向好 建議尋找被低估醫藥股

2026-02-05T  
勁方醫藥啟動GFH375治療胰腺癌註冊性三期臨床試驗

2025-12-05T  
勁方醫藥GFH375聯合療法治療晚期實體瘤研究完成首例入組

2025-10-22T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.